[go: up one dir, main page]

AR123532A1 - Vacuna contra coronavirus, cepas de levadura, métodos de detección, métodos de tratamiento y usos - Google Patents

Vacuna contra coronavirus, cepas de levadura, métodos de detección, métodos de tratamiento y usos

Info

Publication number
AR123532A1
AR123532A1 ARP210102579A ARP210102579A AR123532A1 AR 123532 A1 AR123532 A1 AR 123532A1 AR P210102579 A ARP210102579 A AR P210102579A AR P210102579 A ARP210102579 A AR P210102579A AR 123532 A1 AR123532 A1 AR 123532A1
Authority
AR
Argentina
Prior art keywords
coronavirus
domain
vaccine
amino acid
acid sequence
Prior art date
Application number
ARP210102579A
Other languages
English (en)
Inventor
Hidalgo Tommy Idrovo
Lorena Itati Ibaez
Natalia Brenda Fernandez
Javier Santos
Cecilia Dalessio
Alejandro Daniel Nadra
Florencia Pignataro
Original Assignee
Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet
Univ De Buenos Aires Uba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet, Univ De Buenos Aires Uba filed Critical Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet
Priority to ARP210102579A priority Critical patent/AR123532A1/es
Priority to PCT/US2022/043578 priority patent/WO2023043868A2/en
Priority to EP22870656.0A priority patent/EP4401769A4/en
Publication of AR123532A1 publication Critical patent/AR123532A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Vacuna y obtención de anticuerpos contra coronavirus, cepas de levadura, métodos de detección, métodos de tratamiento y usos. La vacuna contra un coronavirus que comprende el dominio RBD de la proteína espiga de coronavirus deglicosilado y adyuvantes, en donde el dominio RDB es producido en P. pastoris. Entre otras, la secuencia de aminoácidos del dominio RBD puede ser la secuencia SEQ ID Nº 1 o SEQ ID Nº 2, en donde la vacuna puede comprender además uno o varios adyuvantes. Reivindicación 10: Una cepa de levadura transformada, caracterizada porque expresa y libera al medio una proteína que comprende la secuencia de aminoácidos del dominio RBD de la proteína espiga de SARS-CoV-2 unida a una secuencia de aminoácidos de reconocimiento de Sortasa A unida a una etiqueta His6, en donde la expresión es estable. Reivindicación 13: Un método de detección de anticuerpos anti coronavirus, caracterizado porque comprende al menos las siguientes etapas: a. contactar el dominio RBD deglicosilado de la proteína espiga de un coronavirus con una cantidad de una muestra biológica, en donde el dominio RBD es producido en P. pastoris; y b. incubar y revelar.
ARP210102579A 2021-09-16 2021-09-16 Vacuna contra coronavirus, cepas de levadura, métodos de detección, métodos de tratamiento y usos AR123532A1 (es)

Priority Applications (3)

Application Number Priority Date Filing Date Title
ARP210102579A AR123532A1 (es) 2021-09-16 2021-09-16 Vacuna contra coronavirus, cepas de levadura, métodos de detección, métodos de tratamiento y usos
PCT/US2022/043578 WO2023043868A2 (en) 2021-09-16 2022-09-15 Coronavirus vaccine, yeast strains, methods of detection, methods of treatment and uses thereof
EP22870656.0A EP4401769A4 (en) 2021-09-16 2022-09-15 CORONAVIRUS VACCINE, YEAST STRAINS, DETECTION METHODS, TREATMENT METHODS AND ASSOCIATED USES

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP210102579A AR123532A1 (es) 2021-09-16 2021-09-16 Vacuna contra coronavirus, cepas de levadura, métodos de detección, métodos de tratamiento y usos

Publications (1)

Publication Number Publication Date
AR123532A1 true AR123532A1 (es) 2022-12-14

Family

ID=84578120

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210102579A AR123532A1 (es) 2021-09-16 2021-09-16 Vacuna contra coronavirus, cepas de levadura, métodos de detección, métodos de tratamiento y usos

Country Status (3)

Country Link
EP (1) EP4401769A4 (es)
AR (1) AR123532A1 (es)
WO (1) WO2023043868A2 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1618127B1 (en) 2003-04-10 2014-12-10 Novartis Vaccines and Diagnostics, Inc. Immunogenic composition comprising a spike protein of the SARS coronavirus
US7879799B2 (en) 2006-08-10 2011-02-01 Institute For Systems Biology Methods for characterizing glycoproteins and generating antibodies for same
EP3728588A4 (en) * 2017-12-22 2022-03-09 The Broad Institute, Inc. CAS12A SYSTEMS, METHODS AND COMPOSITIONS FOR TARGETED EDIT OF RNA BASES
US11690907B2 (en) * 2018-06-12 2023-07-04 Kbio Holdings Limited Vaccines formed by virus and antigen conjugation
US20210206810A1 (en) * 2019-11-20 2021-07-08 Ingenza Ltd. Detection of Optimal Recombinants Using Fluorescent Protein Fusions
CN112300251B (zh) * 2020-02-24 2022-04-05 成都威斯克生物医药有限公司 抗SARS-CoV-2感染的蛋白及疫苗
US11376320B2 (en) * 2020-03-05 2022-07-05 Iowa State University Research Foundation, Inc. Immunogenic and vaccine compositions against SARS-CoV-2
CN111474350B (zh) * 2020-04-23 2023-07-07 中国林业科学研究院林业研究所 一种检测冠状病毒s1抗原的试剂盒及其非诊断目的的检测方法
RU2720614C9 (ru) * 2020-04-23 2021-02-09 федеральное государственное бюджетное учреждение «Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи» Министерства здравоохранения Российской Федерации Иммунобиологическое средство и способ его использования для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 (варианты)
CN111920946B (zh) * 2020-08-07 2021-05-28 合肥诺为尔基因科技服务有限公司 环二核苷酸修饰铝纳米粒疫苗佐剂-传递系统及基于其的SARS-CoV-2亚单位疫苗

Also Published As

Publication number Publication date
WO2023043868A3 (en) 2023-10-12
EP4401769A4 (en) 2025-07-23
WO2023043868A2 (en) 2023-03-23
EP4401769A2 (en) 2024-07-24

Similar Documents

Publication Publication Date Title
Naglik et al. Candida albicans proteinases and host/pathogen interactions
Naglik et al. Candida albicans secreted aspartyl proteinases in virulence and pathogenesis
Behnsen et al. Secreted Aspergillus fumigatus protease Alp1 degrades human complement proteins C3, C4, and C5
Bechah et al. Identification of rickettsial infections by using cutaneous swab specimens and PCR
CN103498000B (zh) 一种多重pcr法检测水稻检疫性病原菌的引物组及试剂盒和方法
Flockhart et al. Enzyme polymorphism in Trichinella
Tavanti et al. Differential expression of secretory aspartyl proteinase genes (SAP1-10) in oral Candida albicans isolates with distinct karyotypes
Cole et al. Detection of an RNA-dependent RNA polymerase in mitochondria from a mitovirus-infected isolate of the Dutch Elm disease fungus, Ophiostoma novo-ulmi
AR123532A1 (es) Vacuna contra coronavirus, cepas de levadura, métodos de detección, métodos de tratamiento y usos
Al-Damerchi et al. Detection of major virulence factor of Entamoeba histolytica by using PCR technique
Song et al. Establishment of a recombinase-aided isothermal amplification technique to detect Schistosoma japonicum specific gene fragments
Sandhu et al. Molecular detection and identification of Paracoccidioides brasiliensis
Yamaji et al. A salivary cystatin, HlSC-1, from the ixodid tick Haemaphysalis longicornis play roles in the blood-feeding processes
CN106701940A (zh) 一种荧光探针检测血吸虫dna的方法
CN102851264A (zh) 一种白纹伊蚊的Apyrase编码基因及其蛋白制备方法和用途
CN101303349A (zh) 一种猪囊尾蚴病间接elisa检测试剂盒及其制备方法
AL-Hosary Loop-Mediated Isothermal Amplification (LAMP) Assay for Diagnosis of Bovine Babesiosis (Babesia bovis infection) in Egypt: LAMP assay for diagnosis of bovine babesiosis
Sufiate et al. Nematicidal activity of proteases from Euphorbia milii
Cervantes-Sandoval et al. Characterization of Naegleria fowleri strains isolated from human cases of primary amoebic meningoencephalitis in Mexico
Karthikeyan et al. Development and comparison of ELISA and PCR methods for the early detection of Ganoderma disease of coconut
Bonants et al. Characterization and detection of Phytophthora fragariae in plant, water and soil by molecular methods
Suwarsono et al. The Evaluations of Bleach as Decontaminant Solution to Promote The Positivity Rate of Mycobacterium Tuberculosis Culture for Sputum Specimen
CN100510079C (zh) 恶性疟原虫蛋白基因
Koeberle Development of a diagnostic test of Tumorigenic A. vitis in grapevines
CN102692509A (zh) 重组蛋白混合物介导的牛结核病诊断方法及其试剂